Dr. Nicholas Plotnikoff, Non-Executive Chairman
Dr. Plotnikoff has a Ph.D. in pharmacology, with over 20 years of experience in the pharmaceutical industry, having worked in pharmacology, toxicology, and clinical research. He was a professor of pharmacology at the University of Illinois Medical Center in Chicago and played a pioneering role in investigations of the immunological effects of MENK. Dr. Plotnikoff also successfully managed the project teams that developed the NDAs on Traxene (a Valium-like tranquilizer) and Cylert (a non-amphetamine psychostimulant). In basic research, he was the first to identify the central nervous system effects of hypothalamic-releasing factors (brain hormones), resulting in their clinical development for treatment of depression and Parkinson’s disease. Dr. Plotnikoff has co-authored 25 publications with Dr. Andrew Schally, covering basic research in the fields of depression and Parkinson’s disease, and held a number of international patents for the use of MENK in HIV/AIDS and cancer. He is further credited with achieving major breakthroughs in the treatment of certain cancers and of HIV/AIDS. Along with the late Dr. Bernard Bihari (see page xx), Dr. Plotnikoff completed Phase I and early Phase II clinical trials in the U.S. using MENK, and has collaborated with Dr. Joseph Wybran from Belgium on clinical trials for treatment by MENK in patients with HIV/AIDS. Trials continue in China with the support of China Medical University and Professor Shan using MENK, which began in 2007 (as described on page xx). Immune Therapeutics is now partnering with Professor Shan on treating cancer patients with IRT-101 and IRT-102 in China.
Roger Bozarth is Founder and President of The Insurance Advantage, Inc. and Planning for Wealth Preservation, LLC, located in Orlando, Florida, which he founded in 1995. His firm specializes in estate, business, and charitable planning for affluent clients throughout the United States.
In addition to his business experience, Mr. Bozarth is involved in a number of charitable organizations, including the U.S. Dream Academy in Baltimore, MD, and Desire Street Ministries in Atlanta, GA, while serving on the board of Edgewood Children’s Ranch and Love Orlando in Orlando, FL.
Mr. Bozarth attended the University of South Florida where he pursued an Electrical Engineering degree.
Dr. Chalil MD, MBA, FACHE
Dr. Chalil MD, MBA, FACHE is Associate Director, Health Science Executives of Boehringer Ingelheim, the world’s largest privately held pharmaceutical company. Headquartered in Ingelheim, Germany, the Company operates globally in more than 50 countries. In 2012, Boehringer Ingelheim achieved net sales of 19.1 billion (USD); R&D expenditure in the business area of prescription medicines reached a quarter of its net sales.
In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil is the Co-Chair for the Industry Physician Committee of the American Association of Physicians of Indian Origin (AAPI) and has served as Scientific Advisor to AAPI for the past three years. AAPI is the second largest physician organization in the U.S. second only to AMA, and the largest ethnic medical organization in the country. Dr. Chalil is also a Consultant in HIV/STDs President, AIDS Society of India (ASI).
As the former CEO of Clinical Consultants International, he represented prominent healthcare companies, including GE Healthcare, Genpact, HIRCO Group, Godrej Ltd., KLE University, Somaiya Group, Pushpanjali Crosslay Hospital, Excel Life Sciences and various international pharmaceutical firms over the past decade.
Dr. Chalil completed his higher studies in University of Medicine and Dentistry of New Jersey, Davenport University, JJM Medical College and Baylor College of Medicine. He has been a Visiting Professor at various Universities and serves on various company Boards.
Terry Grossman, M.D.
Dr. Grossman is the founder and medical director of the Grossman Wellness Center in Denver, Colorado. His longevity medical practice attracts patients, including many VIPs (such as coauthor Ray Kurzweil) from around the country and the world. He graduated from Brandeis University in 1968 and the University of Florida School of Medicine in 1979. He spent 15 years (from 1980-1995) working as a community family doctor in the Colorado mountains. Dr. Grossman undertook the study of nutritional and anti-aging medicine in 1994 and in 1995 opened the Grossman Wellness Center in Denver, which quickly grew into one of the largest complementary medical centers in the country. He is a member and board certified by the American Academy of Anti-Aging Medicine as well as the American Holistic Medical Association. His special field of interest is nutritional medicine (the treatment of illness with nutrients such as vitamins, minerals, anti-oxidants and natural hormones) and anti-aging medicine. Dr. Grossman is a widely sought lecturer on longevity medicine throughout the U.S. and has presented keynote addresses at anti-aging seminars in Japan, South Korea, South Africa, and elsewhere. He is the author of the Baby Boomers’ Guide to Living Forever (2000), and coauthor with Ray Kurzweil of Fantastic Voyage (2004), and TRANSCEND: Nine Steps to Living Well Forever (2009).
Mak Jawadekar, PH.D.
Mak Jawadekar, Ph.D., is an independent pharmaceutical industry consultant and currently serves on several U.S. and international company boards in scientific advisory and business management capacities. After completing his Ph.D. (Pharmaceutics) at the University of Minnesota, he started working at Pfizer, Inc., and his tenure was over 28 years in length until March 2010, when he opted to take an early retirement. Mak was a Director, R & D Portfolio Management & Performance with the World Wide R & D Division of Pfizer Inc. in Groton/New London, CT, where he was leading efforts in R&D benchmarking metrics for speed, quality and costs to enhance Pharmaceutical R&D productivity.
Mak also advised Pfizer’s R&D business on system solution approaches and best practices, and served as an advisor to Pfizer’s President of Global R&D on Asia-related strategic matters. Prior to that, he spent many years with Pfizer’s Pharmaceutical Sciences Group as a leader, where he held responsibility for Strategic Outsourcing of Drug Products activities and Drug Delivery Technology Assessment functions. Mak also managed strategic-level decisions on external alliances and collaborations, including partnerships, due diligence activities, and licensing and development. His extensive previous Bench R & D experience includes dosage form development/formulations/drug delivery R&D, clinical manufacturing, tech transfer and scale-up operations, and worked closely with Pfizer Global Manufacturing and Consumer Health care divisions.
Dr. Jill Smith
Dr. Jill Smith, an Advisor to the company, is a former Professor of Medicine in the Gastroenterology Division of the Department of Medicine, Hershey Medical Center, Penn State University. Dr. Smith has a long track record of conducting pre-clinical scientific research as well as translational clinical trials in patients. Over the course of her twenty-two years at Penn State University, she has mentored thirty-eight post-doctoral Fellows and students, thereby ensuring continuing excellence in medicine for future generations.
Dr. Smith’s research focus is on disorders of the gastrointestinal tract and pancreas. In her role as a Professor in the College of Medicine’s Internal Medicine Department she treats patients with Inflammatory Bowel Diseases.
Simultaneously, in her role as Professor of Cellular and Molecular Physiology she teaches and conducts basic science research in the graduate school. For over two decades, Dr. Smith has conducted industry-sponsored trials and investigator-initiated research involving inflammatory bowel disease. One of her areas of expertise is in translational medicine.
Another area of expertise for Dr. Smith involves her research on pancreatic cancer. Dr. Smith’s team discovered that growth of pancreatic cancer is controlled by a small protein called gastrin. They further discovered a novel receptor on human pancreas cancer through which gastrin exerts its effects. Dr. Smith’s discovery led to her being the recipient of the Basic Science Research Award, a prestigious award given by the European Pancreas Society for outstanding discoveries in science. Ongoing research using this novel receptor or targeting therapy and early detection of pancreatic cancer is underway. Dr. Smith is also is a co-discoverer of the role of another protein called OGF (Opioid Growth Factor) that inhibits growth of pancreatic cancer. This discovery has been confirmed in both Phase 1 and Phase 2 clinical trials treating patients with advanced pancreatic cancer with OGF.
Dr. Smith was the first ever researcher to carry out a clinical trial of low dose naltrexone. The results of the successful trial in patients suffering from Crohn’s disease has spearheaded ongoing clinical trials by other researchers at several institutions worldwide.
Dr. Smith has been elected as the first woman President of the American Pancreas Association. For three years, she has served as the Chairman of the American Gastroenterology Association’s Research Committee and she currently serves on National Institutes of Health review panels for research grants.
Dr. Smith has chaired a National Cancer Institute workshop on pancreatic cancer and her expertise in pancreatic cancer and translational research has made her a sought-after international speaker in these fields.